Biological aging, Klotho and mitochondria in cardiovascular–kidney–metabolic syndrome
The abstract proposes biological aging as a central link between heart, kidney and metabolic disease, with Klotho, senescence markers and mitochondrial measures as possible staging tools; elamipretide benefits are preclinical and inconclusive in HFpEF trials. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract proposes biological aging as the central substrate linking CKM risk factors to organ failure, describing cardiac, renal and pancreatic β-cell aging mechanisms. [1]
Klotho is described as a kidney-derived endocrine factor whose circulating levels decline with CKD progression and metabolic disease, regulating mitochondrial homeostasis via Sirt1–CHK2. [1]
Elamipretide (SS-31) is said to show functional benefits in numerous preclinical heart failure models, but its effect in an HFpEF trial remains inconclusive. [1]
The source at a glance
- Study type / format
- Abstract of a narrative review or perspective proposing a framework
- Population / context
- People with cardiovascular–kidney–metabolic syndrome and related heart, kidney and metabolic conditions, plus aged renal and failing myocardial tissue samples described in the abstract.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- October 5, 2026
Proposed CKM framework links organ aging to failure
The abstract describes cardiovascular–kidney–metabolic (CKM) syndrome as a framework combining heart failure, chronic kidney disease and metabolic dysfunction. It presents biological aging as the proposed central substrate linking CKM risk factors to organ failure. Cardiac aging is said to promote mitochondrial dysfunction, diastolic stiffening and impaired repair; renal aging to deplete tubular cell renewal, accelerate fibrosis and reduce production of the anti-aging hormone α-Klotho; and pancreatic β-cell aging to drive p16INK4a-mediated senescence and mitochondrial uncoupling that impair first-phase insulin secretion. These are described mechanisms, not demonstrated causes of human outcomes.
Supporting source [1]
Klotho decline and mitochondrial cristae loss in aged kidney
Klotho is described as a kidney-derived endocrine factor whose circulating levels decline with chronic kidney disease progression and metabolic disease. It is said to regulate cellular proliferation and mitochondrial homeostasis through the Sirt1–CHK2 signaling axis. Three-dimensional electron microscopy of aged renal tubular mitochondria reportedly shows age-dependent loss of cristae structural integrity, linked to reduced expression of the MICOS complex, described as the protein scaffold maintaining cristae junction architecture. Volumetric electron microscopy of human failing myocardium reportedly shows distinct mitochondrial structural phenotypes in heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF). These are structural observations, not proof of treatment effects.
Supporting source [1]
Proposed staging markers and preclinical elamipretide evidence
Measuring circulating Klotho, senescence-associated secretory phenotype (SASP) markers and urinary mitochondrial DNA is proposed as a biological staging dimension complementing standard CKM clinical classification. The mitochondria-targeted peptide elamipretide (SS-31) is called the most mature pharmacological intervention targeting inner mitochondrial membrane integrity. It is said to have shown functional benefits in numerous preclinical heart failure models, while the effect in an HFpEF trial remains inconclusive. The abstract therefore outlines a proposed personalized approach in which biological aging phenotype would guide therapy; it does not establish that this approach is validated or that elamipretide benefits people with HFpEF.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. It reports proposed mechanisms, structural microscopy observations and preclinical drug findings; it does not establish human causal effects, validated staging tools or clinical benefit of elamipretide.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lin HY, Tsai C, Chang K, Tsai Y, Chen S, Hung C, Lee J, Kuo H, Kuo M, Chiu Y, Hwang S, Dai D. · europepmc.org · October 5, 2026